What the FDA labels say about taking them together
Dihydroergotamine and posaconazole
Posaconazole's FDA label of August 3, 2026 names dihydroergotamine in its contraindications section; the dihydroergotamine labels PlainMeds reads (4) do not name posaconazole. The posaconazole label: “Noxafil may increase the plasma concentrations of ergot alkaloids which may lead to ergotism.”
Check it at the source: the dihydroergotamine FDA label on DailyMed (effective March 6, 2025, Oceanside Pharmaceuticals); the posaconazole FDA label on DailyMed (effective August 3, 2026, Aurobindo Pharma Limited).
What does the dihydroergotamine label say about posaconazole?
Dihydroergotamine's label (effective March 6, 2025) and its 3 other brand-application labels do not name posaconazole in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Dihydroergotamine Mesylate), NDA020148 (Bausch), as published by Oceanside Pharmaceuticals, effective March 6, 2025 (SPL set 977de209-c53a-4cb4-9f3f-1e850600a9dc), via openFDA; the full label on DailyMed
What does the posaconazole label say about dihydroergotamine?
Posaconazole label, contraindicationsPosaconazole delayed-release tablets may increase the plasma concentrations of ergot alkaloids (ergotamine and dihydroergotamine) which may lead to ergotism [see Drug Interactions (7.2) ].
Source: FDA drug label (Noxafil, NDA022003), Merck Sharp & Dohme LLC, effective February 13, 2026 (SPL set b073b082-7b57-4423-8c06-4fd4263d6f84), via openFDA
Source: FDA drug label (POSACONAZOLE), Aurobindo Pharma Limited, effective August 3, 2026 (SPL set f8a26673-261c-4e8e-b1e1-9e23aaf7f285), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Dihydroergotamine | Posaconazole | |
|---|---|---|
| Labeled for | Migraine | Fungal infections |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $29.44 per mL 4 mg/mL nasal spray | $2.03 per tablet 100 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once